Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Burris, H. A.
Right arrow Articles by Von Hoff, D. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Burris, H. A., 3rd
Right arrow Articles by Von Hoff, D. D.

Journal of Clinical Oncology, Vol 15, 2403-2413, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Improvements in survival and clinical benefit with gemcitabine as first- line therapy for patients with advanced pancreas cancer: a randomized trial

HA Burris 3rd, MJ Moore, J Andersen, MR Green, ML Rothenberg, MR Modiano, MC Cripps, RK Portenoy, AM Storniolo, P Tarassoff, R Nelson, FA Dorr, CD Stephens and DD Von Hoff
Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX 78245, USA.

PURPOSE: Most patients with advanced pancreas cancer experience pain and must limit their daily activities because of tumor-related symptoms. To date, no treatment has had a significant impact on the disease. In early studies with gemcitabine, patients with pancreas cancer experienced an improvement in disease-related symptoms. Based on those findings, a definitive trial was performed to assess the effectiveness of gemcitabine in patients with newly diagnosed advanced pancreas cancer. PATIENTS AND METHODS: One hundred twenty-six patients with advanced symptomatic pancreas cancer completed a lead-in period to characterize and stabilize pain and were randomized to receive either gemcitabine 1,000 mg/m2 weekly x 7 followed by 1 week of rest, then weekly x 3 every 4 weeks thereafter (63 patients), or to fluorouracil (5-FU) 600 mg/m2 once weekly (63 patients). The primary efficacy measure was clinical benefit response, which was a composite of measurements of pain (analgesic consumption and pain intensity), Karnofsky performance status, and weight. Clinical benefit required a sustained (> or = 4 weeks) improvement in at least one parameter without worsening in any others. Other measures of efficacy included response rate, time to progressive disease, and survival. RESULTS: Clinical benefit response was experienced by 23.8% of gemcitabine- treated patients compared with 4.8% of 5-FU-treated patients (P = .0022). The median survival durations were 5.65 and 4.41 months for gemcitabine-treated and 5-FU-treated patients, respectively (P = .0025). The survival rate at 12 months was 18% for gemcitabine patients and 2% for 5-FU patients. Treatment was well tolerated. CONCLUSION: This study demonstrates that gemcitabine is more effective than 5-FU in alleviation of some disease-related symptoms in patients with advanced, symptomatic pancreas cancer. Gemcitabine also confers a modest survival advantage over treatment with 5-FU.


This article has been cited by other articles:


Home page
 Jpn J Clin OncolHome page
T. Shirasaka
Development History and Concept of an Oral Anticancer Agent S-1 (TS-1(R)): Its Clinical Usefulness and Future Vistas
Jpn. J. Clin. Oncol., January 1, 2009; 39(1): 2 - 15.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
M. K. Kim, K. H. Lee, B. I. Jang, T. N. Kim, J. R. Eun, S. H. Bae, H. M. Ryoo, S. A. Lee, and M. S. Hyun
S-1 and Gemcitabine as an Outpatient-based Regimen in Patients with Advanced or Metastatic Pancreatic Cancer
Jpn. J. Clin. Oncol., January 1, 2009; 39(1): 49 - 53.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. A. Dallas, M. J. Gray, L. Xia, F. Fan, G. van Buren II, P. Gaur, S. Samuel, S. J. Lim, T. Arumugam, V. Ramachandran, et al.
Neuropilin-2-Mediated Tumor Growth and Angiogenesis in Pancreatic Adenocarcinoma
Clin. Cancer Res., December 15, 2008; 14(24): 8052 - 8060.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
S. Takano, A. Togawa, H. Yoshitomi, T. Shida, F. Kimura, H. Shimizu, H. Yoshidome, M. Ohtsuka, A. Kato, T. Tomonaga, et al.
Annexin II Overexpression Predicts Rapid Recurrence after Surgery in Pancreatic Cancer Patients Undergoing Gemcitabine-Adjuvant Chemotherapy
Ann. Surg. Oncol., November 1, 2008; 15(11): 3157 - 3168.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
T. Tanaka, M. Ikeda, T. Okusaka, H. Ueno, C. Morizane, A. Hagihara, S. Iwasa, and Y. Kojima
Prognostic Factors in Japanese Patients with Advanced Pancreatic Cancer Treated with Single-agent Gemcitabine as First-line Therapy
Jpn. J. Clin. Oncol., November 1, 2008; 38(11): 755 - 761.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. Marten, N. Zeiss, S. Serba, S. Mehrle, M. von Lilienfeld-Toal, and J. Schmidt
Bortezomib is ineffective in an orthotopic mouse model of pancreatic adenocarcinoma
Mol. Cancer Ther., November 1, 2008; 7(11): 3624 - 3631.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Kim, D. E. Morgan, D. J. Buchsbaum, H. Zeng, W. E. Grizzle, J. M. Warram, C. R. Stockard, L. R. McNally, J. W. Long, J. C. Sellers, et al.
Early Therapy Evaluation of Combined Anti-Death Receptor 5 Antibody and Gemcitabine in Orthotopic Pancreatic Tumor Xenografts by Diffusion-Weighted Magnetic Resonance Imaging
Cancer Res., October 15, 2008; 68(20): 8369 - 8376.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
T. Uwagawa, T. Misawa, T. Sakamoto, R. Ito, T. Gocho, H. Shiba, S. Wakiyama, S. Hirohara, S. Sadaoka, and K. Yanaga
A phase I study of full-dose gemcitabine and regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer
Ann. Onc., October 3, 2008; (2008) mdn640v1.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. G. Haller, M. L. Rothenberg, A. O. Wong, P. M. Koralewski, W. H. Miller Jr, G. Bodoky, N. Habboubi, C. Garay, and L. O. Olivatto
Oxaliplatin Plus Irinotecan Compared With Irinotecan Alone as Second-Line Treatment After Single-Agent Fluoropyrimidine Therapy for Metastatic Colorectal Carcinoma
J. Clin. Oncol., October 1, 2008; 26(28): 4544 - 4550.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
B. R. Tan, W. S. Brenner, J. Picus, S. Marsh, F. Gao, C. Fournier, P. M. Fracasso, J. James, J. L. Yen-Revollo, and H. L. Mcleod
Phase I study of biweekly oxaliplatin, gemcitabine and capecitabine in patients with advanced upper gastrointestinal malignancies
Ann. Onc., October 1, 2008; 19(10): 1742 - 1748.
[Abstract] [Full Text] [PDF]

Home page
 Br Med BullHome page
S. A. Danovi, H. H. Wong, and N. R. Lemoine
Targeted therapies for pancreatic cancer
Br. Med. Bull., September 1, 2008; 87(1): 97 - 130.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
L. N. Kaliberova, D. L. Della Manna, V. Krendelchtchikova, M. E. Black, D. J. Buchsbaum, and S. A. Kaliberov
Molecular chemotherapy of pancreatic cancer using novel mutant bacterial cytosine deaminase gene
Mol. Cancer Ther., September 1, 2008; 7(9): 2845 - 2854.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. S. Azmi, Z. Wang, R. Burikhanov, V. M. Rangnekar, G. Wang, J. Chen, S. Wang, F. H. Sarkar, and R. M. Mohammad
Critical role of prostate apoptosis response-4 in determining the sensitivity of pancreatic cancer cells to small-molecule inhibitor-induced apoptosis
Mol. Cancer Ther., September 1, 2008; 7(9): 2884 - 2893.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G. Gravis, F. Bladou, N. Salem, A. Goncalves, B. Esterni, J. Walz, S. Bagattini, M. Marcy, S. Brunelle, and P. Viens
Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer
Ann. Onc., September 1, 2008; 19(9): 1624 - 1628.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
B. Chauffert, F. Mornex, F. Bonnetain, P. Rougier, C. Mariette, O. Bouche, J. F. Bosset, T. Aparicio, L. Mineur, A. Azzedine, et al.
Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study
Ann. Onc., September 1, 2008; 19(9): 1592 - 1599.
[Abstract] [Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
P Ghaneh, E Costello, and J P Neoptolemos
Biology and management of pancreatic cancer
Postgrad. Med. J., September 1, 2008; 84(995): 478 - 497.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. A. Morgan, L. A. Parsels, L. E. Kollar, D. P. Normolle, J. Maybaum, and T. S. Lawrence
The Combination of Epidermal Growth Factor Receptor Inhibitors with Gemcitabine and Radiation in Pancreatic Cancer
Clin. Cancer Res., August 15, 2008; 14(16): 5142 - 5149.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Bernhard, D. Dietrich, W. Scheithauer, D. Gerber, G. Bodoky, T. Ruhstaller, B. Glimelius, E. Bajetta, J. Schuller, P. Saletti, et al.
Clinical Benefit and Quality of Life in Patients With Advanced Pancreatic Cancer Receiving Gemcitabine Plus Capecitabine Versus Gemcitabine Alone: A Randomized Multicenter Phase III Clinical Trial--SAKK 44/00-CECOG/PAN.1.3.001
J. Clin. Oncol., August 1, 2008; 26(22): 3695 - 3701.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. Koeberle, P. Saletti, M. Borner, D. Gerber, D. Dietrich, C. B. Caspar, W. Mingrone, K. Beretta, F. Strasser, T. Ruhstaller, et al.
Patient-Reported Outcomes of Patients With Advanced Biliary Tract Cancers Receiving Gemcitabine Plus Capecitabine: A Multicenter, Phase II Trial of the Swiss Group for Clinical Cancer Research
J. Clin. Oncol., August 1, 2008; 26(22): 3702 - 3708.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. R. Goffin and D. Tu
Phase II Stopping Rules That Employ Response Rates and Early Progression
J. Clin. Oncol., August 1, 2008; 26(22): 3715 - 3720.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
U. Distler, J. Souady, M. Hulsewig, I. Drmic-Hofman, J. Haier, A. Denz, R. Grutzmann, C. Pilarsky, N. Senninger, K. Dreisewerd, et al.
Tumor-associated CD75s- and iso-CD75s-gangliosides are potential targets for adjuvant therapy in pancreatic cancer
Mol. Cancer Ther., August 1, 2008; 7(8): 2464 - 2475.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. S. Pino, M. Balsamo, F. Di Modugno, M. Mottolese, M. Alessio, E. Melucci, M. Milella, D. J. McConkey, U. Philippar, F. B. Gertler, et al.
Human Mena+11a Isoform Serves as a Marker of Epithelial Phenotype and Sensitivity to Epidermal Growth Factor Receptor Inhibition in Human Pancreatic Cancer Cell Lines
Clin. Cancer Res., August 1, 2008; 14(15): 4943 - 4950.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. Merchant and J. Berlin
Past and Future of Pancreas Cancer: Are We Ready to Move Forward Together?
J. Clin. Oncol., July 20, 2008; 26(21): 3478 - 3480.
[Full Text] [PDF]

Home page
 JCOHome page
G. R. Varadhachary, R. A. Wolff, C. H. Crane, C. C. Sun, J. E. Lee, P. W.T. Pisters, J.-N. Vauthey, E. Abdalla, H. Wang, G. A. Staerkel, et al.
Preoperative Gemcitabine and Cisplatin Followed by Gemcitabine-Based Chemoradiation for Resectable Adenocarcinoma of the Pancreatic Head
J. Clin. Oncol., July 20, 2008; 26(21): 3487 - 3495.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. B. Evans, G. R. Varadhachary, C. H. Crane, C. C. Sun, J. E. Lee, P. W.T. Pisters, J.-N. Vauthey, H. Wang, K. R. Cleary, G. A. Staerkel, et al.
Preoperative Gemcitabine-Based Chemoradiation for Patients With Resectable Adenocarcinoma of the Pancreatic Head
J. Clin. Oncol., July 20, 2008; 26(21): 3496 - 3502.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. Dhillon, B. B. Aggarwal, R. A. Newman, R. A. Wolff, A. B. Kunnumakkara, J. L. Abbruzzese, C. S. Ng, V. Badmaev, and R. Kurzrock
Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer
Clin. Cancer Res., July 15, 2008; 14(14): 4491 - 4499.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
Y. J. Chua and J. R. Zalcberg
Pancreatic cancer--is the wall crumbling?
Ann. Onc., July 1, 2008; 19(7): 1224 - 1230.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. R. McWilliams, W. R. Bamlet, J. M. Cunningham, E. L. Goode, M. de Andrade, L. A. Boardman, and G. M. Petersen
Polymorphisms in DNA Repair Genes, Smoking, and Pancreatic Adenocarcinoma Risk
Cancer Res., June 15, 2008; 68(12): 4928 - 4935.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. D. Fowler, J. A. Brown, K. A. Johnson, and Z. Suo
Kinetic Investigation of the Inhibitory Effect of Gemcitabine on DNA Polymerization Catalyzed by Human Mitochondrial DNA Polymerase
J. Biol. Chem., May 30, 2008; 283(22): 15339 - 15348.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Heinrich, B. C. Pestalozzi, M. Schafer, A. Weber, P. Bauerfeind, A. Knuth, and P.-A. Clavien
Prospective Phase II Trial of Neoadjuvant Chemotherapy With Gemcitabine and Cisplatin for Resectable Adenocarcinoma of the Pancreatic Head
J. Clin. Oncol., May 20, 2008; 26(15): 2526 - 2531.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. Nieto, M. L. Grossbard, and P. Kozuch
Metastatic Pancreatic Cancer 2008: Is the Glass Less Empty?
Oncologist, May 1, 2008; 13(5): 562 - 576.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
K. Miyanishi, H. Ishiwatari, T. Hayashi, M. Takahashi, Y. Kawano, K. Takada, H. Ihara, T. Okuda, K. Takanashi, S. Takahashi, et al.
A Phase I Trial of Arterial Infusion Chemotherapy with Gemcitabine and 5-Fluorouracil for Unresectable Advanced Pancreatic Cancer after Vascular Supply Distribution via Superselective Embolization
Jpn. J. Clin. Oncol., April 1, 2008; 38(4): 268 - 274.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Okazaki, L. Jiao, P. Chang, D. B. Evans, J. L. Abbruzzese, and D. Li
Single-Nucleotide Polymorphisms of DNA Damage Response Genes Are Associated with Overall Survival in Patients with Pancreatic Cancer
Clin. Cancer Res., April 1, 2008; 14(7): 2042 - 2048.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. F. Hezel and A. X. Zhu
Systemic Therapy for Biliary Tract Cancers
Oncologist, April 1, 2008; 13(4): 415 - 423.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
W. F. Regine, K. A. Winter, R. A. Abrams, H. Safran, J. P. Hoffman, A. Konski, A. B. Benson, J. S. Macdonald, M. R. Kudrimoti, M. L. Fromm, et al.
Fluorouracil vs Gemcitabine Chemotherapy Before and After Fluorouracil-Based Chemoradiation Following Resection of Pancreatic Adenocarcinoma: A Randomized Controlled Trial
JAMA, March 5, 2008; 299(9): 1019 - 1026.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
J. L. Abbruzzese
Adjuvant Therapy for Surgically Resected Pancreatic Adenocarcinoma
JAMA, March 5, 2008; 299(9): 1066 - 1067.
[Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
A. Maeda, N. Boku, A. Fukutomi, S. Kondo, T. Kinoshita, M. Nagino, and K. Uesaka
Randomized Phase III Trial of Adjuvant Chemotherapy with Gemcitabine versus S-1 in Patients with Resected Pancreatic Cancer: Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC-01)
Jpn. J. Clin. Oncol., March 1, 2008; 38(3): 227 - 229.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
B. Laquente, C. Lacasa, M. M. Ginesta, O. Casanovas, A. Figueras, M. Galan, I. G. Ribas, J. R. Germa, G. Capella, and F. Vinals
Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model
Mol. Cancer Ther., March 1, 2008; 7(3): 638 - 647.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. P. Kim and G. E. Gallick
Gemcitabine Resistance in Pancreatic Cancer: Picking the Key Players
Clin. Cancer Res., March 1, 2008; 14(5): 1284 - 1285.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Laheru, E. Lutz, J. Burke, B. Biedrzycki, S. Solt, B. Onners, I. Tartakovsky, J. Nemunaitis, D. Le, E. Sugar, et al.
Allogeneic Granulocyte Macrophage Colony-Stimulating Factor-Secreting Tumor Immunotherapy Alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune Activation
Clin. Cancer Res., March 1, 2008; 14(5): 1455 - 1463.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
H. Burris III and C. Rocha-Lima
New Therapeutic Directions for Advanced Pancreatic Cancer: Targeting the Epidermal Growth Factor and Vascular Endothelial Growth Factor Pathways
Oncologist, March 1, 2008; 13(3): 289 - 298.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. Small Jr, J. Berlin, G. M. Freedman, T. Lawrence, M. S. Talamonti, M. F. Mulcahy, A. B. Chakravarthy, A. A. Konski, M. M. Zalupski, P. A. Philip, et al.
Full-Dose Gemcitabine With Concurrent Radiation Therapy in Patients With Nonmetastatic Pancreatic Cancer: A Multicenter Phase II Trial
J. Clin. Oncol., February 20, 2008; 26(6): 942 - 947.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Pharmacy PracticeHome page
A. A. Garcia
Small Molecules: Big Changes in the Cancer Treatment Paradigm
Journal of Pharmacy Practice, February 1, 2008; 21(1): 17 - 35.
[Abstract] [PDF]

Home page
 Ann OncolHome page
S. Boeck, T. Hoehler, G. Seipelt, R. Mahlberg, A. Wein, A. Hochhaus, H.-P. Boeck, B. Schmid, E. Kettner, M. Stauch, et al.
Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer
Ann. Onc., February 1, 2008; 19(2): 340 - 347.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. M. Booth and I. Tannock
Reflections on Medical Oncology: 25 Years of Clinical Trials Where Have We Come and Where Are We Going?
J. Clin. Oncol., January 1, 2008; 26(1): 6 - 8.
[Full Text] [PDF]

Home page
 Ann OncolHome page
A. Duffy, J. Kortmansky, G. K. Schwartz, M. Capanu, S. Puleio, B. Minsky, L. Saltz, D. P. Kelsen, and E. M. O'Reilly
A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma
Ann. Onc., January 1, 2008; 19(1): 86 - 91.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
A. N. Shah, J. M. Summy, J. Zhang, S. I. Park, N. U. Parikh, and G. E. Gallick
Development and Characterization of Gemcitabine-Resistant Pancreatic Tumor Cells
Ann. Surg. Oncol., December 1, 2007; 14(12): 3629 - 3637.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
S A Khan, A Miras, M Pelling, and S D Taylor-Robinson
Cholangiocarcinoma and its management
Gut, December 1, 2007; 56(12): 1755 - 1756.
[Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
L. C. DeRosier, S. M. Vickers, K. R. Zinn, Z. Huang, W. Wang, W. E. Grizzle, J. Sellers, C. R. Stockard Jr., T. Zhou, P. G. Oliver, et al.
TRA-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotopic pancreatic tumor growth
Mol. Cancer Ther., December 1, 2007; 6(12): 3198 - 3207.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
F. Joly, J. Vardy, M. Pintilie, and I. F. Tannock
Quality of life and/or symptom control in randomized clinical trials for patients with advanced cancer
Ann. Onc., December 1, 2007; 18(12): 1935 - 1942.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Hassan, V. C. Broaddus, S. Wilson, D. J. Liewehr, and J. Zhang
Anti Mesothelin Immunotoxin SS1P in Combination with Gemcitabine Results in Increased Activity against Mesothelin-Expressing Tumor Xenografts
Clin. Cancer Res., December 1, 2007; 13(23): 7166 - 7171.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
R. V. Iyer, J. Gibbs, B. Kuvshinoff, M. Fakih, J. Kepner, N. Soehnlein, D. Lawrence, and M. M. Javle
A Phase II Study of Gemcitabine and Capecitabine in Advanced Cholangiocarcinoma and Carcinoma of the Gallbladder: A Single-Institution Prospective Study
Ann. Surg. Oncol., November 1, 2007; 14(11): 3202 - 3209.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. Rajasekhar and T. J. George Jr.
Gemcitabine-Induced Reversible Posterior Leukoencephalopathy Syndrome: A Case Report and Review of the Literature
Oncologist, November 1, 2007; 12(11): 1332 - 1335.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. H. Kulke, L. S. Blaszkowsky, D. P. Ryan, J. W. Clark, J. A. Meyerhardt, A. X. Zhu, P. C. Enzinger, E. L. Kwak, A. Muzikansky, C. Lawrence, et al.
Capecitabine Plus Erlotinib in Gemcitabine-Refractory Advanced Pancreatic Cancer
J. Clin. Oncol., October 20, 2007; 25(30): 4787 - 4792.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Shimamura, R. E. Royal, M. Kioi, A. Nakajima, S. R. Husain, and R. K. Puri
Interleukin-4 Cytotoxin Therapy Synergizes with Gemcitabine in a Mouse Model of Pancreatic Ductal Adenocarcinoma
Cancer Res., October 15, 2007; 67(20): 9903 - 9912.
[Abstract] [Full Text] [PDF]